KR20230051152A - β2-아드레날린 수용체 효능제인 페노테롤 하이드로브로마이드 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물 - Google Patents

β2-아드레날린 수용체 효능제인 페노테롤 하이드로브로마이드 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20230051152A
KR20230051152A KR1020237001143A KR20237001143A KR20230051152A KR 20230051152 A KR20230051152 A KR 20230051152A KR 1020237001143 A KR1020237001143 A KR 1020237001143A KR 20237001143 A KR20237001143 A KR 20237001143A KR 20230051152 A KR20230051152 A KR 20230051152A
Authority
KR
South Korea
Prior art keywords
myopia
composition
subject
eye
years
Prior art date
Application number
KR1020237001143A
Other languages
English (en)
Korean (ko)
Inventor
안드레이 브이. 트카첸코
타티아나 브이. 트카첸코
Original Assignee
더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 filed Critical 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕
Publication of KR20230051152A publication Critical patent/KR20230051152A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237001143A 2020-06-11 2021-06-09 β2-아드레날린 수용체 효능제인 페노테롤 하이드로브로마이드 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물 KR20230051152A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063037891P 2020-06-11 2020-06-11
US63/037,891 2020-06-11
PCT/US2021/036614 WO2021252626A1 (fr) 2020-06-11 2021-06-09 MÉTHODES ET COMPOSITIONS POUR PRÉVENIR ET TRAITER LA MYOPIE À L'AIDE DE BROMHYDRATE DE FÉNOTÉROL, UN AGONISTE DU RÉCEPTEUR β2-ADRÉNERGIQUE, ET DE SES DÉRIVÉS

Publications (1)

Publication Number Publication Date
KR20230051152A true KR20230051152A (ko) 2023-04-17

Family

ID=78846491

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001143A KR20230051152A (ko) 2020-06-11 2021-06-09 β2-아드레날린 수용체 효능제인 페노테롤 하이드로브로마이드 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물

Country Status (7)

Country Link
EP (1) EP4164607A4 (fr)
JP (1) JP2023530679A (fr)
KR (1) KR20230051152A (fr)
CN (1) CN116194094A (fr)
CA (1) CA3182397A1 (fr)
IL (1) IL298974A (fr)
WO (1) WO2021252626A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569903B2 (en) * 1999-12-07 2003-05-27 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
WO2010125416A1 (fr) * 2009-04-27 2010-11-04 Raouf Rekik Administration de médicaments dans le segment antérieur et le segment postérieur de l'oeil
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
WO2015138700A1 (fr) * 2014-03-13 2015-09-17 Bodor Laboratories, Inc. Utilisation de zwitterions anticholinergiques sélectionnés
WO2016172712A2 (fr) * 2015-04-23 2016-10-27 Sydnexis, Inc. Composition ophtalmique
JP2022536460A (ja) * 2019-06-10 2022-08-17 ジェニヴィジョン インク． 視力障害を治療するための方法及び製剤

Also Published As

Publication number Publication date
EP4164607A4 (fr) 2024-07-10
IL298974A (en) 2023-02-01
CN116194094A (zh) 2023-05-30
CA3182397A1 (fr) 2021-12-16
JP2023530679A (ja) 2023-07-19
WO2021252626A1 (fr) 2021-12-16
EP4164607A1 (fr) 2023-04-19

Similar Documents

Publication Publication Date Title
AU2017239563B2 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
Kaiti et al. Role of Atropine in the control of Myopia Progression-A Review
KR20230051130A (ko) 선택적 히스타민 h1-수용체 길항제인 레보카바스틴 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물
KR20230051152A (ko) β2-아드레날린 수용체 효능제인 페노테롤 하이드로브로마이드 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물
KR20230051155A (ko) 베르베리다세아엔 알칼로이드인 베르베린 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물
KR20230051154A (ko) 스핑고신-1-포스페이트 수용체 조절제인 핑골리모드 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물
KR20230051156A (ko) 선택적 신경 산화질소 합성효소(nnos) 저해제인 s-메틸-l-티오시트룰린 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물
KR20230051153A (ko) 히스톤 데아세틸레이스(hdac) 저해제인 트라이코스타틴 a 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물
US20230138414A1 (en) Methods and compositions for preventing and treating myopia
CN115634226A (zh) 一种采用长春西汀治疗近视的方法
NZ623037B2 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism